Evidence map›Paper›PMID 38744738›Full record

ArticleMikrochimica acta2024

Hollow versatile Ag@Pt alloy nanoparticles with nanozyme activity for detection and photothermal sterilization of Helicobacter pylori.

Leheng Zhang, Li Ji, Mingxia Lin, Ruizhuo Liu, Huiyi Yang, Jingjing Zhao, Suqing Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. [Advances in Nanozyme-Aptamer Systems for the Detection of Foodborne Pathogens].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Leheng ZhangDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, People's Republic of China.
Li JiDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, People's Republic of China.
Mingxia LinDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, People's Republic of China.
Ruizhuo LiuDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, People's Republic of China.
Huiyi YangDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, People's Republic of China.
Jingjing ZhaoDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, People's Republic of China. jjzhao@gdut.edu.cn.
Suqing ZhaoDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, People's Republic of China. sqzhao@gdut.edu.cn.ORCID http://orcid.org/0000-0002-8458-671X

Funding

GuangDong Basic and Applied Basic Research Foundation 2020A1515010952GuangDong Basic and Applied Basic Research Foundation 2021A1515110331GuangDong Basic and Applied Basic Research Foundation 2021A1515220016GuangDong Basic and Applied Basic Research Foundation 2022A1515011807Guangdong Provincial Introduction of Innovative Research and Development Team 2021TDZ09Guangdong Provincial Introduction of Innovative Research and Development Team 2021YDZ06Guangzhou Municipal Science and Technology Project 201903010034Guangzhou Municipal Science and Technology Project 202102020682；202201010308National Natural Science Foundation of China No. 22108041Science and Technology Foundation Key R&D Program of Guangdong Province 2019B020209009Science and Technology Foundation Key R&D Program of Guangdong Province 2019B020218009
6 · The paper itself

Abstract

In view of a large number of people infected with Helicobacter pylori (H. pylori) with great harm followed, there is an urgent need to develop a non-invasive, easy-to-operate, and rapid detection method, and to identify effective sterilization strategies. In this study, highly specific nanoprobes with nanozyme activity, Ag@Pt nanoparticles (NPs) with the antibody, were utilized as a novel lateral flow immunoassay (LFIA). The optical label (Ag@Pt NPs) was enhanced by the introduction of the chromogenic substrate 3,3',5,5'-tetramethylbenzidine (TMB) and compared with a gold nanoparticles (Au NPs) optical label. Under the optimal condition, Ag@Pt-LFIA and TMB-enhanced Ag@Pt-LFIA for H. pylori were successfully established, two of which were over twofold and 100-fold more sensitive than conventional visual Au NP-based LFIA, respectively. Furthermore, Ag@Pt NPs with the antibody irradiated with NIR laser (808 nm) at a power intensity of 550 mW/cm

Indexed as

AlloysHelicobacter pyloriMetal NanoparticlesPlatinumSilverAnti-Bacterial AgentsBenzidinesGoldHumansImmunoassayLimit of DetectionSterilizationAlloysAnti-Bacterial AgentsBenzidinesGoldPlatinumSilverAg@Pt nanoparticlesHelicobacter pyloriLateral flow immunoassayNanozyme activityPhotothermal sterilization

Identifiers

PMID38744738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.